HUP0203559A3 - Polymorphic forms of sertraline hydrochloride, process for their preparation and pharmaceutical compositions containing them - Google Patents

Polymorphic forms of sertraline hydrochloride, process for their preparation and pharmaceutical compositions containing them

Info

Publication number
HUP0203559A3
HUP0203559A3 HU0203559A HUP0203559A HUP0203559A3 HU P0203559 A3 HUP0203559 A3 HU P0203559A3 HU 0203559 A HU0203559 A HU 0203559A HU P0203559 A HUP0203559 A HU P0203559A HU P0203559 A3 HUP0203559 A3 HU P0203559A3
Authority
HU
Hungary
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
polymorphic forms
sertraline hydrochloride
Prior art date
Application number
HU0203559A
Other languages
English (en)
Original Assignee
Ciba Sc Holding Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8243113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0203559(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ciba Sc Holding Ag filed Critical Ciba Sc Holding Ag
Publication of HUP0203559A2 publication Critical patent/HUP0203559A2/hu
Publication of HUP0203559A3 publication Critical patent/HUP0203559A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU0203559A 1999-10-29 2000-10-23 Polymorphic forms of sertraline hydrochloride, process for their preparation and pharmaceutical compositions containing them HUP0203559A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99810981 1999-10-29
PCT/EP2000/010416 WO2001032601A1 (en) 1999-10-29 2000-10-23 Polymorphic forms of sertraline hydrochloride

Publications (2)

Publication Number Publication Date
HUP0203559A2 HUP0203559A2 (hu) 2003-03-28
HUP0203559A3 true HUP0203559A3 (en) 2008-01-28

Family

ID=8243113

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203559A HUP0203559A3 (en) 1999-10-29 2000-10-23 Polymorphic forms of sertraline hydrochloride, process for their preparation and pharmaceutical compositions containing them

Country Status (17)

Country Link
US (2) US6872853B1 (hu)
EP (1) EP1224160B1 (hu)
JP (1) JP2003513062A (hu)
CN (1) CN1384816A (hu)
AR (1) AR026293A1 (hu)
AT (1) ATE409684T1 (hu)
AU (1) AU1386301A (hu)
CA (1) CA2387135A1 (hu)
DE (1) DE60040406D1 (hu)
HU (1) HUP0203559A3 (hu)
IL (2) IL149050A0 (hu)
MX (1) MXPA02004255A (hu)
MY (1) MY141509A (hu)
TR (1) TR200201146T2 (hu)
TW (1) TWI260315B (hu)
WO (1) WO2001032601A1 (hu)
ZA (1) ZA200203254B (hu)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1133459B1 (en) * 1998-11-27 2006-01-11 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride form v
EP1632473A1 (en) * 1998-11-27 2006-03-08 Teva Pharmaceutical Industries Ltd Sertraline hydrochloride polymorphs
US6500987B1 (en) * 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
US6495721B1 (en) 1999-08-09 2002-12-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride Form II and methods for the preparation thereof
US7442838B2 (en) * 1999-10-29 2008-10-28 Ciba Specialty Chemicals Corp. Polymorphic forms of sertraline hydrochloride
US20050119351A1 (en) * 1999-10-29 2005-06-02 Van Der Schaaf Paul A. Polymorphic forms of sertraline hydrochloride
EP1774965A3 (en) * 1999-12-21 2007-10-10 Teva Pharmaceutical Industries Ltd Novel sertraline hydrochloride polymorph, processes for preparing them, compositions containing them and methods of using them
HUP0204010A3 (en) * 1999-12-21 2006-02-28 Teva Pharma Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and their use
IN192343B (hu) * 2000-05-26 2004-04-10 Ranbaxy Lab Ltd
EP1397343A1 (en) * 2001-05-31 2004-03-17 Orion Corporation Fermion Process for preparing sertraline hydrochloride polymorphic form ii
WO2003093217A1 (en) * 2002-04-29 2003-11-13 Teva Pharmaceutical Industries Ltd. Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof
KR101161935B1 (ko) * 2002-06-27 2012-07-03 인터디지탈 테크날러지 코포레이션 사용자 장치 측정값 정보를 피어 투 피어 방식으로 교환하는 무선 네트워크 제어기
US7186863B2 (en) 2003-05-23 2007-03-06 Transform Pharmaceuticals, Inc. Sertraline compositions
RU2376279C2 (ru) 2003-11-04 2009-12-20 Сипла Лимитед Способ получения полиморфов ингибитора повторного захвата серотонина (варианты)
US20070173536A1 (en) * 2004-02-06 2007-07-26 Ciba Specialty Chemicals Holding Inc. Crystalline forms of zolmitriptan
US20070100165A1 (en) * 2005-06-09 2007-05-03 Ronen Borochovitz Process for preparation of sertraline hydrochloride form I
US7518019B2 (en) 2006-06-01 2009-04-14 Hetero Drugs Limited Processes for preparing sertraline hydrochloride crystalline forms
CA2594198A1 (en) * 2007-07-20 2009-01-20 Apotex Pharmachem Inc. A novel process for the preparation of sertraline hydrochloride form ii
US9993793B2 (en) 2010-04-28 2018-06-12 The Procter & Gamble Company Delivery particles
US9186642B2 (en) 2010-04-28 2015-11-17 The Procter & Gamble Company Delivery particle
WO2012138690A2 (en) 2011-04-07 2012-10-11 The Procter & Gamble Company Conditioner compositions with increased deposition of polyacrylate microcapsules
CN103458859A (zh) 2011-04-07 2013-12-18 宝洁公司 具有增强的聚丙烯酸酯微胶囊的沉积的个人清洁组合物
WO2012138696A2 (en) 2011-04-07 2012-10-11 The Procter & Gamble Company Shampoo compositions with increased deposition of polyacrylate microcapsules
CN105061217A (zh) * 2015-06-30 2015-11-18 徐静 枸橼酸舍曲林的2种晶型及其制备方法
CN112552188B (zh) * 2020-12-17 2023-07-28 山西仟源医药集团股份有限公司 盐酸舍曲林晶型i的制备方法
CN113588626B (zh) * 2021-08-24 2024-05-24 上海师范大学 一种苯丙氨酸对映体的拉曼光谱检测方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US5082970A (en) 1991-03-06 1992-01-21 Pfizer Inc. Process for recycling amine isomer
GB9114947D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline
US5248699A (en) 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US5734083A (en) 1996-05-17 1998-03-31 Torcan Chemical Ltd. Sertraline polymorph
HU222341B1 (hu) 1996-12-18 2003-06-28 Richter Gedeon Vegyészeti Gyár Rt. Eljárás sertralin előállítására és az eljárásban alkalmazott intermedier
DE69713353D1 (de) * 1997-12-11 2002-07-18 Torcan Chemical Ltd Sertralin-Polymorph mit verbesserter Wasserlöslichkeit
PT1064250E (pt) 1998-03-18 2004-09-30 Ciba Sc Holding Ag Processo para a hidrogenacao catalitica cis-selectiva ciclo-hexilidenaminas
JP2000026378A (ja) 1998-07-03 2000-01-25 Sumika Fine Chemicals Co Ltd 塩酸セルトラリンの製法
US6500987B1 (en) 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
EP1133459B1 (en) 1998-11-27 2006-01-11 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride form v
US6495721B1 (en) 1999-08-09 2002-12-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride Form II and methods for the preparation thereof
HUP0204010A3 (en) 1999-12-21 2006-02-28 Teva Pharma Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and their use

Also Published As

Publication number Publication date
US6872853B1 (en) 2005-03-29
JP2003513062A (ja) 2003-04-08
US20040132828A1 (en) 2004-07-08
CN1384816A (zh) 2002-12-11
TWI260315B (en) 2006-08-21
EP1224160B1 (en) 2008-10-01
WO2001032601A1 (en) 2001-05-10
MY141509A (en) 2010-05-14
DE60040406D1 (de) 2008-11-13
MXPA02004255A (es) 2002-10-17
TR200201146T2 (tr) 2004-12-21
IL149050A (en) 2007-03-08
HUP0203559A2 (hu) 2003-03-28
US6939992B2 (en) 2005-09-06
AR026293A1 (es) 2003-02-05
IL149050A0 (en) 2002-11-10
AU1386301A (en) 2001-05-14
ZA200203254B (en) 2003-07-22
EP1224160A1 (en) 2002-07-24
CA2387135A1 (en) 2001-05-10
ATE409684T1 (de) 2008-10-15

Similar Documents

Publication Publication Date Title
HUP0203559A3 (en) Polymorphic forms of sertraline hydrochloride, process for their preparation and pharmaceutical compositions containing them
HUP0200758A3 (en) Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them
HUP0203257A3 (en) Polymorphic forms of atorvastatin calcium, process for their preparations and pharmaceutical compositions containing them
HUP0105108A3 (en) Amide compounds, process for their preparation and pharmaceutical compositions containing them
HUP0203669A3 (en) Renin inhibitors, process for their preparation, pharmaceutical compositions containing them and their use
HUP0204245A3 (en) Novel n-azabicyclo-amide derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0203316A3 (en) Amino-triazolopyridine derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0204010A3 (en) Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and their use
AU4465200A (en) Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
HUP0400236A3 (en) Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride, process for their preparation and pharmaceutical compositions containing them
HUP0200572A3 (en) Amine derivatives as protease inhibitors process for their preparation, pharmaceutical compositions containing them and their use
AU2953699A (en) Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
HUP0102723A3 (en) New diphenylurea derivatives, process for their preparation and pharmaceutical compositions containing them
IL162456A0 (en) A novel polymorph of sertraline hydrochloride and composition containing thereof, novel methods for preparation of sertraline hydrochlor
HUP0201516A3 (en) 13-methyl-erythromycin derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0200881A3 (en) Renin inhibitors, process for preparation of the compounds, pharmaceutical compositions containing them and their use
HUP0201753A2 (en) Pyridopyranoazepine derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0200580A3 (en) Polymorphic crystalline forms of celecoxib, process their preparation and pharmaceutical compositions containing them
HUP0201402A3 (en) Bis-sulfonamides, process for their preparation and pharmaceutical compositions containing them
HUP0203184A3 (en) Isoxazolecarboxamide derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0401163A3 (en) L crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation and pharmaceutical compositions containing the crystalline forms
HUP0204318A3 (en) Torsemide polymorphic forms, process for their preparation, pharmaceutical compositions containing them and their use
HUP0202934A3 (en) Arylsulfonamido-substituted hydroxamic acid derivatives, process for their preparation, pharmaceutical compositions containing them and use thereof
HUP0202731A3 (en) O-anisamide derivatives, process for their preparation and pharmaceutical compositions containing them
IL164903A0 (en) Processes for preparation of polymorphic form II of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished